Patent US4465197A successfully refreshed from Google Patents.
Patent US6900692B2 successfully refreshed from Google Patents.
Patent US6133024A successfully refreshed from Google Patents.
← Back to Patent Explorer
US6133024A Expired / Lapsed US ⏱️ 0.0 years remaining

Gene expression control

Assignee: Aventis Pharma SA
•
Filing: 1998-05-07
•
Granted: 2000-10-17
•
Expires: 2018-05-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to new vectors, pharmaceutical compositions containing them, and their therapeutical uses. More particularly, it relates to new molecules capable of acting, in a very selective and efficacious way, on the expression of genes.

Inventors

  • 👤 Claude Helene
  • 👤 Carine Giovannangeli

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 14:04
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61P; A61P31/00; A61P31/12; A61P31/20; A61P31/22; A61P35/00; C12N15/1131; C12N15/1132; C12N15/1136; A61K; A61K38/00; C12N2310/00; C12N2310/10; C12N2310/15; C12N2310/152; C12N2310/50; C12N2310/53; C12N2310/531; C12N2310/532; Y; Y10; Y10S; Y10S977/00; Y10S977/70; Y10S977/788; Y10S977/802; Y10S977/902; Y10S977/904; Y10S977/915; Y10S977/916; Y10S977/92

Claims Analysis

Total Claims: 23
Claim 1
Independent Claim 39 words
A recombinant vector, wherein the vector comprises a double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNA in a target cell.
Claim 2
Dependent Claim 39 words
A recombinant vector, wherein the vector comprises a double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNA in a target cell.
Claim 3
Dependent Claim 42 words
The vector according to claim 1, wherein the encoded RNA comprises: (a) a first region which forms a double helix with the single-stranded target nucleic acid, and (b) a second region which forms a triple helix with the double helix thus formed.
Claim 4
Dependent Claim 44 words
The vector according to claim 2, wherein the first region of the RNA forms a double helix by interaction of Watson-Crick type with the targeted single-stranded nucleic acid and then the second region forms a triple helix with this double helix by hydrogen bonds.
Claim 5
Dependent Claim 27 words
The vector according to claim 2, wherein the encoded RNA further comprises an oligonucleotide arm of from 3 to 6 bases between the first and second regions.
Claim 6
Dependent Claim 30 words
The vector according to claim 2, wherein the two regions of the encoded RNA are interrupted, and wherein the encoded RNA further comprises an oligonucleotide arm connecting the two regions.
Claim 7
Dependent Claim 35 words
The vector according to claim 1, wherein the RNA comprises first and second regions which forms a double helix with each other, and thereafter forming a triple helix with the single stranded target nucleic acid.
Claim 8
Dependent Claim 36 words
The vector according to claim 6, wherein the two regions of the RNA form the double helix by pairing of Watson-Crick type, and this double helix interacts with the single-stranded target nucleic acid by hydrogen bonds.
Claim 9
Dependent Claim 128 words
The vector according to claim 1, wherein the RNA comprises: (a) a first region which forms a double helix with an oligopurine region of the single-stranded target nucleic acid, (b) a second region which forms a triple helix with the double helix formed between the first region and the oligopurine region of the single stranded target nucleic acid, (c) a first oligonucleotide arm connecting the first and second regions, (d) a third region which forms a double helix with an oligopyrimidine region of the single-stranded target nucleic acid, (e) a fourth region which forms a triple helix with the double helix formed between the third region and the oligopyrimidine region of the single-stranded target nucleic acid, and (f) a second oligonucleotide arm connecting the third and fourth region.
Claim 10
Dependent Claim 12 words
The vector according to claim 1, wherein the transcription signals are constitutive.
Claim 11
Dependent Claim 12 words
The vector according to claim 1, wherein the transcription signals are regulated.
Claim 12
Dependent Claim 19 words
The vector according to claim 1, wherein the transcription signal is a promoter controlled specifically by RNA polymerase III.
Claim 13
Dependent Claim 36 words
The vector according to claim 1, wherein the double stranded DNA sequence is selected from the group consisting of SEQ ID Nos. 2, 3, 4, 5, 6, 7, 8, 10, 11, 13, 14, 15 and 17.
Claim 14
Dependent Claim 12 words
The vector according to claim 1, which is a replication defective virus.
Claim 15
Dependent Claim 25 words
The vector according to claim 13, wherein the virus is selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, cytomegalovirus and vaccinia virus.
Claim 16
Dependent Claim 13 words
The vector according to claim 14, wherein the virus is a defective adenovirus.
Claim 17
Dependent Claim 58 words
A recombinant viral vector selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, cytomegalovirus and vaccinia virus, wherein the viral vector comprises more than one double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNAs in a target cell.
Claim 18
Dependent Claim 58 words
A recombinant viral vector selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, cytomegalovirus and vaccinia virus, wherein the viral vector comprises more than one double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNAs in a target cell.
Claim 19
Dependent Claim 28 words
The vector according to claim 16, wherein each of the double-stranded DNA sequences encodes a different RNA which forms a triple helix with the single-stranded target nucleic acid.
Claim 20
Dependent Claim 20 words
A composition comprising a vector according to claim 1, wherein said vector is complexed with DEAE-dextran, nuclear proteins, or lipids.
Claim 21
Dependent Claim 18 words
A composition comprising a vector according to claim 1, wherein said vector is incorporated into liposomes or nanoparticles.
Claim 22
Dependent Claim 127 words
An RNA comprising: (a) a first region which forms a double helix with an oligopurine region of a single-stranded target nucleic acid, (b) a second region which forms a triple helix with the double helix formed between the first region and the oligopurine region of the single stranded target nucleic acid, (c) a first oligonucleotide arm connecting the first and second regions, (d) a third region which forms a double helix with an oligopyrimidine region of the single-stranded target nucleic acid, (e) a fourth region which forms a triple helix with the double helix formed between the third region and the oligopyrimidine region of the single-stranded target nucleic acid, and (f) a second oligonucleotide arm connecting the third and fourth region, wherein two triple helices are formed.
Claim 23
Dependent Claim 127 words
An RNA comprising: (a) a first region which forms a double helix with an oligopurine region of a single-stranded target nucleic acid, (b) a second region which forms a triple helix with the double helix formed between the first region and the oligopurine region of the single stranded target nucleic acid, (c) a first oligonucleotide arm connecting the first and second regions, (d) a third region which forms a double helix with an oligopyrimidine region of the single-stranded target nucleic acid, (e) a fourth region which forms a triple helix with the double helix formed between the third region and the oligopyrimidine region of the single-stranded target nucleic acid, and (f) a second oligonucleotide arm connecting the third and fourth region, wherein two triple helices are formed.

References Cited (Backward Citations)

WO1991006626A2 Cited
WO1992019732A1 Cited
WO1993012230A1 Cited
FR2687411A1 Cited
US5624803A Cited
US5700657A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2003-10-17 2004-04-17 2004-10-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2007-10-17 2008-04-17 2008-10-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2011-10-17 2012-04-17 2012-10-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag